PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.68
-0.21 (-0.59%)
At close: 4:02PM EDT

35.75 +0.07 (0.20%)
After hours: 5:03PM EDT

Stock chart is not supported by your current browser
Previous Close35.89
Open35.82
Bid0.00 x 1400
Ask0.00 x 29200
Day's Range35.54 - 35.92
52 Week Range31.67 - 39.43
Volume14,236,565
Avg. Volume21,677,395
Market Cap208.713B
Beta0.95
PE Ratio (TTM)9.91
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.82%)
Ex-Dividend Date2018-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • How to Invest in Diabetes Stocks
    Motley Fool4 hours ago

    How to Invest in Diabetes Stocks

    Here's everything you need to know about investing in the fast-growing diabetes market.

  • Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb
    Market Realist9 hours ago

    Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb

    In the first quarter, Bristol-Myers Squibb’s (BMY) Opdivo witnessed sales close to $1.5 billion, driven by a robust rise in demand across the approved indications of lung cancer, renal cell carcinoma (or RCC), head and neck cancer, and melanoma. Further, the company is also witnessing robust uptake of Opdivo as adjuvant therapy for melanoma patients. To know more about Opdivo as an adjuvant melanoma therapy, please read Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018.

  • This Collaboration Is Expected to Boost Merck’s Long-Term Growth
    Market Realist9 hours ago

    This Collaboration Is Expected to Boost Merck’s Long-Term Growth

    Merck & Company (MRK) has entered into a global strategic oncology collaboration with Eisai for the worldwide codevelopment and co-commercialization of Eisai’s Lenvima. Merck and Eisai will jointly develop and commercialize Lenvima as a monotherapy and in combination with Keytruda.

  • A Brief Overview of Merck’s First-Quarter Performance
    Market Realist11 hours ago

    A Brief Overview of Merck’s First-Quarter Performance

    Merck & Company (MRK) reported revenue of $10.0 billion in Q1 2018 compared to $9.4 billion in Q1 2017, which reflected a ~6% rise YoY (year-over-year) and a ~4% fall sequentially. In Q1 2018, Merck saw a ~2% positive impact from foreign exchange.

  • The Wall Street Journal12 hours ago

    [$$] The Heated Quest for Opioid Alternatives

    Rising abuse of prescription painkillers is intensifying a search for alternatives to addictive opioids. Despite that toll, opioids remain in widespread use because they are powerful painkillers, and many attempts to develop new therapies have failed. LLC, a company that conducts clinical trials and specializes in pain studies.

  • Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval
    Zacks13 hours ago

    Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval

    The Dow endured another volatile week marked by key geopolitical developments.

  • Pfizer’s Products with Declining Revenues in Q1 2018
    Market Realist15 hours ago

    Pfizer’s Products with Declining Revenues in Q1 2018

    Pfizer’s (PFE) portfolio includes some products that are losing market share due to competition from other products in the market. Enbrel, the blockbuster drug, reported a 14% decline to $506 million in the first quarter. BeneFix’s revenues declined 2% to $147 million in the first quarter, driven by a 13% decline in international sales to $79 million, offset by a 16% growth in US sales to $68 million.

  • Reuters23 hours ago

    Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

    An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc (PFE.N) in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) said on Friday it was considering the judgment and remained committed to pursuing cases involving "misuse of market power". "The ACCC brought this appeal because it was concerned that Pfizer's use of its market position as supplier of the top selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers," Chairman Rod Sims said in a statement.

  • Reuters23 hours ago

    Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

    An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) said on Friday it was considering the judgment and remained committed to pursuing cases involving "misuse of market power". "The ACCC brought this appeal because it was concerned that Pfizer's use of its market position as supplier of the top selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers," Chairman Rod Sims said in a statement.

  • The Wall Street Journal23 hours ago

    [$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities

    Pfizer Inc. has agreed to pay nearly $24 million to resolve allegations that it violated federal law by using a charity to pay Medicare patients’ out-of-pocket costs for the company’s prescription drugs, federal prosecutors said. The settlement, with the U.S. Attorney’s Office in Boston, resolves allegations stemming from an investigation into charities that help patients pay for prescription drugs using donations from pharmaceutical companies.

  • Reutersyesterday

    Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

    The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.

  • Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
    Reutersyesterday

    Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

    The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.

  • Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says
    Bloombergyesterday

    Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says

    Pfizer Inc. used a “purportedly independent” charity to help it sharply raise the price of a heart drug, shielding patients from the increase while Medicare picked up the higher costs, the U.S. Justice Department said Thursday in a civil settlement announcement. Pfizer will pay about $24 million in the anti-kickback settlement, the government said in a statement.

  • MarketWatchyesterday

    Pfizer to pay $23.85 million to settle kickback allegations

    The Department of Justice said on Thursday that global pharmaceutical company Pfizer, Inc. settled allegations that it used a foundation as a conduit to pay the copays of Medicare patients taking three Pfizer drugs, in violation of the False Claims Act, and will pay $23.85 million to resolve the claims. Under the Anti-Kickback Statute, pharmaceutical companies are prohibited from offering, directly or indirectly, any payment-which includes paying patients' copay obligations-to induce Medicare patients to purchase the company's drugs.

  • Pfizer's Tafamadis Gets Breakthrough Therapy Designation
    Zacksyesterday

    Pfizer's Tafamadis Gets Breakthrough Therapy Designation

    Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.

  • Pfizer’s Growth Drivers in Q1 2018
    Market Realistyesterday

    Pfizer’s Growth Drivers in Q1 2018

    As we’ve already seen, Pfizer’s (PFE) products are segregated into two segments: Innovative Health and Essential Health. These products were Pfizer’s growth drivers in the first segment: BMP2, Chantix/Champix, Eliquis, Genotropin, Ibrance, Lipitor, Norvasc, Sulperazon, Sutent, Xalkori, Xeljanz, Xtandi, and a few others.

  • Reuters2 days ago

    Drug maker Pfizer to pay $23.85 mln to settle claims it paid kickbacks

    Drug maker Pfizer will pay $23.85 million to settle civil charges that it illegally paid kickbacks by using a foundation as a "conduit" to cover co-pay costs for Medicare patients taking three of the company's drugs, the U.S. Justice Department said Thursday. As part of the settlement, the company will also enter a corporate integrity agreement with the inspector general for the Department of Health and Human Services, which will require the company to implement new compliance measures.

  • InvestorPlace2 days ago

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.

  • 3 Big Pharma Stocks with Huge Future Growth Potential
    InvestorPlace2 days ago

    3 Big Pharma Stocks with Huge Future Growth Potential

    You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.

  • Pfizer’s Performance across Geographies in Q1 2018
    Market Realist2 days ago

    Pfizer’s Performance across Geographies in Q1 2018

    As we’ve already seen, Pfizer’s (PFE) revenues increased 1% to $12.9 billion in the first quarter, driven by increased sales of its Innovative Health products. Pfizer reported a decrease of 5% in US sales in the first quarter. For the first quarter, the Innovative Health segment reported growth of 1% in revenues to $4.5 billion, while the Essential Health segment reported a 19% decline in revenues to $1.7 billion.

  • Pfizer’s Segment Performances in Q1 2018
    Market Realist2 days ago

    Pfizer’s Segment Performances in Q1 2018

    Pfizer’s (PFE) business is segregated into two segments: Innovative Health and Essential Health. The above chart compares the revenue trend for Pfizer since Q1 2017. The Innovative Health segment reported a 6% growth in revenues to $7.8 billion in the first quarter.

  • Financial Times2 days ago

    [$$] Pfizer under pressure to resolve shortage of life-saving EpiPen

    to do more to tackle shortages of the life-saving medicine in a sign of its growing frustration with the Big Pharma company. Although Mylan owns the rights to the EpiPen — which can stave off deadly anaphylactic shock — it subcontracts manufacturing of the auto-injector to Meridian Medical, a division of Pfizer. The US Food and Drug Administration put the medicine on its official shortages list earlier this month.

  • Financial Times2 days ago

    [$$] Pfizer agrees to pay nearly $24m to settle kickback claims

    has agreed to pay almost $24m to settle claims it paid kickbacks to Medicare patients who used its medications, the US Department of Justice said on Thursday. The pharmaceutical company allegedly used a third-party foundation to route payments to patients using three Pfizer drugs, according to the DOJ. Patients using the US Medicare system have some of the cost of treatment paid for by the government, but also have to make a partial “co-pay” payment.

  • TheStreet.com2 days ago

    Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

    The pharma industry spent $3.45 billion on television ads in 2017 and none of those ads mentioned drug prices. The Trump administration wants to change that. In his Rose Garden speech earlier this month, President Trump suggested that direct-to-consumer ads include mandatory pricing information along with risk issues and other educational information.

  • Pfizer’s Quarterly Revenue Trend in Q1 2018
    Market Realist2 days ago

    Pfizer’s Quarterly Revenue Trend in Q1 2018

    Pfizer (PFE) reported revenues of $12.9 billion for the first quarter, which was a 1% growth compared to $12.8 million in Q1 2017. The growth in revenues was driven by a strong performance of its Innovative Health segment, partially offset by lower sales of its Essential Health products.